Ribonucleic Acid News and Research

RSS

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

A new study provides insights into the persistence of extra-neutralizing properties of mRNA vaccine-induced antibodies resulting in protection against the Omicron variant of SARS-CoV-2.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

Researchers evaluate the risk of the P681R, N501Y, and D614G mutations of current interest co-occurring naturally due to convergent evolution.

4 Jan 2022

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Researchers evaluate the effects of a third dose of the BNT162b2 mRNA vaccine on antibody titers and breakthrough infections in healthcare workers.

4 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

CDC report shows COVID vaccines safe for children, serious side effects rare

Researchers determine the characteristics and clinical outcomes of COVID-19 in children and adolescents 18 years or younger.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs).

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Researchers assess the real-world effectiveness of a third booster dose of the Pfizer-BioNTech BNT162b2 vaccine against the initial two-dose regimen.

29 Dec 2021

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Researchers assess vaccine effectiveness of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission.

28 Dec 2021

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Double-dose mRNA COVID vaccines effective among dialysis patients

Researchers assess the impact of lesser initial vaccine response and subsequent waning antibody levels on clinical outcomes among maintenance dialysis.

28 Dec 2021

Ribonucleic Acid News and Research

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Transplant recipients benefit from a COVID-19 vaccine booster

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

The impact of natural selection on sequence diversity in SARS-CoV-2

CDC report shows COVID vaccines safe for children, serious side effects rare

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Minimal nAb titers against Omicron in the elderly after 3rd dose

Echinacea, a potent antiviral against SARS-CoV-2

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Double-dose mRNA COVID vaccines effective among dialysis patients

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News